IP Library Granted Patent US 12,722,014
Granted Patent B2
US 12,722,014 · App. 18/256,841 · Granted Sep 1, 2026

Method of treating drug resistant hypertension and heart failure with preserved ejection fraction by combined drug treatment with baropacing and beta blockers

Inventor: Michael Burnam (Ashland, OR)
Assignee: BaroPace, Inc.
A61N1/36564A61K38/556
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,722,014
App. No.
18/256,841
Granted
Sep 1, 2026
Kind
B2
Abstract

A method of treating a patient with drug resistant hypertension (“DRH”) and/or heart failure with preserved ejection fraction (“HFpEF ”) including the steps of: treating the patient with angiotensin converting enzyme inhibitor (“ACEI”) and/or an angiotensin receptor blocking [ARB] drug and cardiac pacing the patient as controlled by an algorithm. Performance may be improved by simultaneously withholding administration of any beta-1 selective beta adrenergic blockers. The method may also include the steps of administering to a patient a therapeutic amount of a beta blocker having intrinsic sympathomimetic activity (“ISA”) and pacing the heart of a patient using the algorithm.

Claims (67)

1 . A method of treatment, the method comprising:

administering one or more of an angiotensin converting enzyme inhibitor (ACEI) treatment and an angiotensin receptor blocking (ARB) treatment to a patient;

administering a beta blocker intrinsic sympathomimetic activity (ISA) treatment to the patient;

receiving a first blood pressure value at a first time subsequent to providing the at least one or more of the ACEI treatment and the ARB treatment and subsequent to providing the ISA treatment;

determining that the first blood pressure value deviates from a target blood pressure value by at least a threshold amount;

determining a first pacing rate of a pacing device based on the first blood pressure value and an artificial intelligence (AI) trend analysis;

outputting the first pacing rate to the pacing device; and

administering, by the pacing device, a first pacing therapy to the patient based on the first pacing rate.

2 . The method of claim 1 , wherein determining the first pacing rate of the pacing device is performed in real-time upon receiving the first blood pressure value or determining that the first blood pressure deviates from the target blood pressure value by at least the threshold amount.

3 . The method of claim 1 , wherein the first pacing rate is approximately 10% greater than a baseline atrial pacing rate.

4 . The method of claim 1 , further comprising:

receiving a second blood pressure value at a second time subsequent to the first time;

determining that the second blood pressure value deviates from the target blood pressure value by at least the threshold amount;

determining a second pacing rate of the pacing device; and

outputting the second pacing rate to the pacing device.

5 . The method of claim 4 , further comprising:

administering, by the pacing device, a second pacing therapy to the patient based on the second pacing rate.

6 . The method of claim 1 , wherein the first blood pressure value is a systolic blood pressure (SBP) value.

7 . The method of claim 1 , further comprising:

receiving a second blood pressure value at a second time subsequent to the first time;

determining that the second blood pressure value is one of: within the threshold amount of the target blood pressure value, lower than the first blood pressure value by a threshold pressure value; and

maintaining the first pacing rate of the pacing device.

8 . A system for providing treatment comprising:

a first module configured to administer one or more of an angiotensin converting enzyme inhibitor (ACEI) treatment and an angiotensin receptor blocking (ARB) treatment to a patient;

a second module configured to provide administer a beta blocker intrinsic sympathomimetic activity (ISA) treatment to the patient;

a pacing device configured to output electric pacing signals based on pacing rates; and

at least one processor operatively coupled to a memory storing computer-readable instructions that, when executed by the at least one processor, cause the at least one processor to:

receive a first blood pressure value at a first time subsequent to providing the one or more of the ACEI treatment and the ARB treatment and subsequent to providing the ISA treatment;

determine that the first blood pressure value from a target blood pressure value by at least a threshold amount;

based on the first blood pressure value and an artificial intelligence (AI) trend analysis executed by an AI module, and

output the first pacing rate to the pacing device; and

the pacing device configured to administer a first pacing therapy to the patient based on the first pacing rate.

9 . The system of claim 8 , wherein the computer-readable instructions, when executed by the at least one processor, further cause the at least one processor to determine the first pacing rate of the pacing device in real-time upon receiving the first blood pressure value or determining that the first blood pressure value deviates from the target blood pressure value by at least the threshold amount.

10 . The system of claim 8 , wherein the first pacing rate is approximately 10% greater than a baseline atrial pacing rate.

11 . The system of claim 8 , wherein the computer-readable instructions, when executed by the processor, further cause the at least one processor to:

receive a second blood pressure value at a second time subsequent to the first time;

determine that the second blood pressure value deviates from the target blood pressure value by at least the threshold amount; and

determine a second pacing rate of the pacing device; and

output the second pacing rate to the pacing device.

12 . The system of claim 11 , wherein the computer-readable instructions, when executed by the processor, further cause the at least one processor to:

administer a second pacing therapy to the patient based on the second pacing rate.

13 . The system of claim 8 , wherein the first blood pressure value is a systolic blood pressure (SBP) value.

14 . The system of claim 8 , wherein the computer-readable instructions, when executed by the processor, further cause the at least one processor to:

receive a second blood pressure value at a second time subsequent to the first time;

determine that the second blood pressure value is one of: within the threshold amount of the target blood pressure value and lower than the first blood pressure value by a threshold pressure value; and

maintain the first pacing rate of the pacing device.

15 . A system comprising:

a pacing device configured to output electric pacing signals based on pacing rates; and

at least one processor operatively coupled to a memory storing computer-readable instructions that, when executed by the at least one processor, cause the at least one processor to:

receive a first blood pressure value from a patient at a first time subsequent to administration of one or more of an angiotensin converting enzyme inhibitor (ACEI) treatment and an angiotensin receptor blocking (ARB) treatment to the patient and subsequent to administration of a beta blocker intrinsic sympathomimetic activity (ISA) treatment to the patient;

determine that the first blood pressure value deviates from a target blood pressure value by at least a threshold amount;

determine a first pacing rate of a pacing device based on the first blood pressure value and an artificial intelligence (AI) trend analysis executed by an AI module, and

output the first pacing rate to the pacing device; and

the pacing device configured to administer a first pacing therapy to the patient based on the first pacing rate.

16 . The system of claim 15 , wherein the computer-readable instructions, when executed by the processor, further cause the at least one processor to:

receive a second blood pressure value at a second time subsequent to the first time;

determine that the second blood pressure value deviates from the target blood pressure value by at least the threshold amount;

determine a second pacing rate of the pacing device; and

output the second pacing rate to the pacing device.

17 . The system of claim 16 , wherein the computer-readable instructions, when executed by the processor, further cause the at least one processor to:

administer a second pacing therapy to the patient based on the second pacing rate.

18 . The system of claim 15 , wherein the computer-readable instructions, when executed by the processor, further cause the at least one processor to:

receive a second blood pressure value at a second time subsequent to the first time;

determine that the second blood pressure value is one of: within the threshold amount of the target blood pressure value and lower than the first blood pressure value by a threshold pressure value; and

maintain the first pacing rate of the pacing device.

19 . The system of claim 15 , wherein the computer-readable instructions, when executed by the at least one processor, further cause the at least one processor to determine the first pacing rate of the pacing device in real-time upon receiving the first blood pressure value or determining that the first blood pressure value deviates from the target blood pressure value by at least the threshold amount.

20 . The system of claim 15 , wherein the first pacing rate is approximately 10% greater than a baseline atrial pacing rate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2023
From: BURNAM, MICHAEL
To: BAROPACE, INC.
Reel/Frame 063915/0984 →
Continuity (3)
Provisional Application 63237029 · Aug 25, 2021
Provisional Application 63123951 · Dec 10, 2020
Related Publication 20240017077A1 · Jan 18, 2024
References Cited (34)
US 5225401A · Seymour · 1993 [cited by applicant]
US 6487450B1 · Chen · 2002 [cited by applicant]
US 7142911B2 · Boileau et al. · 2006 [cited by applicant]
US 8043215B2 · Zhang et al. · 2011 [cited by applicant]
US 11612352B1 · Kohli et al. · 2023 [cited by applicant]
US 20030045910A1 · Sorensen · 2003 [cited by examiner]
US 20040106953A1 · Yomtov · 2004 [cited by examiner]
US 20040106954A1 · Whitehurst · 2004 [cited by examiner]
US 20050137626A1 · Pastore et al. · 2005 [cited by applicant]
US 20090092964A1 · Liggett · 2009 [cited by applicant]
US 20110213435A1 · Rom · 2011 [cited by applicant]
US 20120035486A1 · Zhang et al. · 2012 [cited by applicant]
US 20190111014A1 · Sturrock et al. · 2019 [cited by applicant]
US 20190232065A1 · Perschbacher · 2019 [cited by examiner]
US 20190299004A1 · Hahn · 2019 [cited by examiner]
US 20200305713A1 · Sipe et al. · 2020 [cited by applicant]
US 20220040487A1 · Burnam · 2022 [cited by examiner]
US 20260000900A1 · Burnam et al. · 2026 [cited by applicant]
WO 2004033036 · 2004 [cited by applicant]
WO 2020096982A1 · 2020 [cited by applicant]
WO 2020210060A1 · 2020 [cited by applicant]
WO WO2021194543A1 · 2021 [cited by examiner]
WO 2022046326 · 2022 [cited by applicant]
Stéphane Laurent, Antihypertensive drugs, Pharmacological Research, vol. 124, 2017, pp. 116-125, ISSN 1043-6618, https://doi.org/10.1016/j.phrs.2017.07.026. (https://www.sciencedirect.com/science/article/pii/S1043661817… [cited by applicant]
International Search Report and Written Opinion Issued in International Application No. PCT/US2021/059557, mailed on Mar. 17, 2022. [cited by applicant]
Office Action of IL Application No. 303494, dated Nov. 23, 2025, 5 pages. [cited by applicant]
Examination Report for Indian Patent Application No. 202447019877, dated Feb. 4, 2026, 9 pages. [cited by applicant]
Office Action for Canadian Patent Application No. 3204319, mailed Jan. 6, 2026, 5 pages. [cited by applicant]
Extended European Search Report and Written Opinion for Application No. 25201005.3 dated Feb. 20, 2026. [cited by applicant]
Extended European Search Report for European Application No. 21904096.1, dated Jan. 26, 2024, 06 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/041289, dated Mar. 7, 2024, 10 Pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/059557, dated on Jun. 22, 2023, 11 Pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/041289, dated Nov. 29, 2022, 13 Pages. [cited by applicant]
Examination Report for Indian Patent Application No. 202347044987, dated Jul. 17, 2026, 9 Pages. [cited by applicant]